Cargando…

Topical Propranolol Improves Epistaxis Control in Hereditary Hemorrhagic Telangiectasia (HHT): A Randomized Double-Blind Placebo-Controlled Trial

Epistaxis is a common debilitating manifestation in hereditary hemorrhagic telangiectasia (HHT), due to mucocutaneous telangiectases. The epistaxis can be difficult to control despite available treatments. Dysregulated angiogenesis has been shown to be associated with telangiectases formation. Topic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mei-Zahav, Meir, Gendler, Yulia, Bruckheimer, Elchanan, Prais, Dario, Birk, Einat, Watad, Muhamad, Goldschmidt, Neta, Soudry, Ethan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7601781/ https://www.ncbi.nlm.nih.gov/pubmed/32998220 http://dx.doi.org/10.3390/jcm9103130

Ejemplares similares

Topical propranolol improves epistaxis in patients with hereditary hemorrhagic telangiectasia - a preliminary report
por: Mei-Zahav, Meir, et al.
Publicado: (2017)

Prospective pilot study of Floseal® for the treatment of anterior epistaxis in patients with hereditary hemorrhagic telangiectasia (HHT)
por: Lee, John M., et al.
Publicado: (2019)

Dynamic Hyperinflation While Exercising—A Potential Predictor of Pulmonary Deterioration in Cystic Fibrosis
por: Shmueli, Einat, et al.
Publicado: (2023)

TIMolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (TIM-HHT)—A Prospective, Randomized, Double-Blind, Controlled, Cross-Over Trial
por: Andorfer, Kornelia E. C., et al.
Publicado: (2022)

Hereditary Hemorrhagic Telangiectasia (HHT) and Survival: The Importance of Systematic Screening and Treatment in HHT Centers of Excellence
por: de Gussem, Els M., et al.
Publicado: (2020)

Long-term efficacy assessment of current treatment options for epistaxis in HHT
por: Dür, Cilgia, et al.
Publicado: (2021)

Quality of life in patients with hereditary haemorrhagic telangiectasia (HHT)
por: Zarrabeitia, Roberto, et al.
Publicado: (2017)

Catheter ablation of left‐sided accessory pathways in small children
por: Fogelman, Rami, et al.
Publicado: (2019)

Videofluoroscopy compared with clinical feeding evaluation in children with suspected aspiration
por: Stafler, Patrick, et al.
Publicado: (2022)

HHT-Related Epistaxis and Pregnancy—A Retrospective Survey and Recommendations for Management from an Otorhinolaryngology Perspective
por: Andorfer, Kornelia E. C., et al.
Publicado: (2022)

Silicone septal splint for recurrent epistaxis in HHT patients: experience of a national referral centre
por: Matti, Elina, et al.
Publicado: (2023)

The therapeutic efficacy of propranolol in children with recurrent primary epistaxis
por: Bjelakovic, Bojko, et al.
Publicado: (2013)

A case report of hepatopulmonary syndrome in hereditary hemorrhagic telangiectasia (HHT): Not all right-to-left shunting in HHT is due to pulmonary arteriovenous malformations
por: Krishnan, Sheila, et al.
Publicado: (2018)

Weekly epistaxis duration as an indicator of epistaxis severity in hereditary hemorrhagic telangiectasia—Preliminary results from a randomized controlled trial
por: Wu, Vincent, et al.
Publicado: (2021)

Screening for pulmonary and brain vascular malformations is the North American standard of care for patients with hereditary hemorrhagic telangiectasia (HHT): A survey of HHT Centers of Excellence
por: Kilian, Alexandra, et al.
Publicado: (2020)

Complex Catheter-Based Structural Heart Reconstruction in a Patient With Tricuspid Atresia and Björk Palliative Conduit
por: Schamroth Pravda, Nili, et al.
Publicado: (2021)

The Amplatzer duct occluder (ADOII) and Piccolo devices for patent ductus arteriosus closure: a large single institution series
por: Bruckheimer, Elchanan, et al.
Publicado: (2023)

Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients
por: Guilhem, Alexandre, et al.
Publicado: (2017)

Vigilance in the Decision-Making Process Regarding Termination of Pregnancy Following Prenatal Diagnosis of Congenital Heart Disease—Application of the ‘Conflict Decision-Making Model’
por: Gendler, Yulia, et al.
Publicado: (2022)

Diode laser in the treatment of epistaxis in patients with hereditary haemorrhagic telangiectasia
por: FIORELLA, M.L., et al.
Publicado: (2012)

Topically Applied Etamsylate: A New Orphan Drug for HHT-Derived Epistaxis (Antiangiogenesis through FGF Pathway Inhibition)
por: Albiñana, Virginia, et al.
Publicado: (2019)

European Reference Network For Rare Vascular Diseases (VASCERN) Outcome Measures For Hereditary Haemorrhagic Telangiectasia (HHT)
por: Shovlin, Claire L., et al.
Publicado: (2018)

Antithrombotic Therapy in Hereditary Hemorrhagic Telangiectasia: Real-World Data from the Gemelli Hospital HHT Registry
por: Gaetani, Eleonora, et al.
Publicado: (2020)

Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers
por: Al-Samkari, Hanny, et al.
Publicado: (2019)

Whole genome sequences discriminate hereditary hemorrhagic telangiectasia phenotypes by non-HHT deleterious DNA variation
por: Joyce, Katie E., et al.
Publicado: (2022)

Lactose-Containing Dry-Powder Inhalers for Patients with Cow’s Milk Protein Allergy—The Conundrum; A National Survey of Pediatric Pulmonologists and Allergologists
por: Bar-On, Ophir, et al.
Publicado: (2022)

Randomized, double-blind, placebo-controlled, crossover trial of oral doxycycline for epistaxis in hereditary hemorrhagic telangiectasia
por: Thompson, K. P., et al.
Publicado: (2022)

Synthetic dural graft septoplasty in epistaxis from hereditary hemorrhagic telangiectasia
por: Burckhardt B, Wilfred, et al.
Publicado: (2013)

Epistaxis in hereditary hemorrhagic telangiectasia: an evidence based review of surgical management
por: Chin, Christopher J., et al.
Publicado: (2016)

Endoscopic surgical treatment of epistaxis in hereditary haemorrhagic telangiectasia: our experience
por: Pagella, Fabio, et al.
Publicado: (2021)

Development and validation of a quality of life measurement scale specific to hereditary hemorrhagic telangiectasia: the QoL-HHT
por: Le, Thi Thao Truc, et al.
Publicado: (2022)

Very low dose bevacizumab for the treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia
por: Thompson, Andrew B., et al.
Publicado: (2014)

Can Iron Treatments Aggravate Epistaxis in Some Patients With Hereditary Hemorrhagic Telangiectasia?
por: Shovlin, Claire L., et al.
Publicado: (2016)

Hereditary hemorrhagic telangiectasia presenting as a recurrent epistaxis in an adolescent: A case report
por: Acharya, Ratna, et al.
Publicado: (2021)

A comparative study of propranolol versus silver nitrate cautery in the treatment of recurrent primary epistaxis in children
por: Ahmed, Ahmed E, et al.
Publicado: (2015)

Simple Method for Controlling Epistaxis
Publicado: (1891)

Simple Method of Controlling Epistaxis
Publicado: (1891)

Endoglin involvement in integrin-mediated cell adhesion as a putative pathogenic mechanism in hereditary hemorrhagic telangiectasia type 1 (HHT1)
por: Rossi, Elisa, et al.
Publicado: (2015)

European Reference Network for Rare Vascular Diseases (VASCERN) position statement on cerebral screening in adults and children with hereditary haemorrhagic telangiectasia (HHT)
por: Eker, Omer F., et al.
Publicado: (2020)

Efficacy of TIMOLOL nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia. A double-blind, randomized, placebo-controlled trial
por: Dupuis-Girod, Sophie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_buhjp0ed4k7t4aifjplcf2ht6o